Chardan Capital Estimates Immuneering FY2025 Earnings

Immuneering Co. (NASDAQ:IMRX) – Equities research analysts at Chardan Capital issued their FY2025 earnings per share estimates for Immuneering in a report issued on Monday, March 24th. Chardan Capital analyst G. Livshits forecasts that the company will earn ($1.65) per share for the year. Chardan Capital has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Immuneering’s current full-year earnings is ($1.86) per share.

A number of other brokerages have also weighed in on IMRX. Morgan Stanley lowered shares of Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. Needham & Company LLC restated a “buy” rating and set a $12.00 price objective on shares of Immuneering in a report on Friday, March 21st.

Immuneering Stock Up 1.2 %

Shares of IMRX stock opened at $1.66 on Thursday. Immuneering has a 12-month low of $1.00 and a 12-month high of $3.83. The firm has a fifty day moving average of $1.77 and a 200-day moving average of $2.00. The firm has a market capitalization of $59.57 million, a price-to-earnings ratio of -0.84 and a beta of -0.32.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.16).

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IMRX. Corsair Capital Management L.P. acquired a new position in Immuneering during the 3rd quarter worth approximately $25,000. Tang Capital Management LLC bought a new stake in shares of Immuneering in the fourth quarter worth $27,000. Marshall Wace LLP bought a new stake in shares of Immuneering in the fourth quarter worth $47,000. First Manhattan CO. LLC. acquired a new position in Immuneering during the fourth quarter worth $71,000. Finally, XTX Topco Ltd grew its position in Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock valued at $72,000 after purchasing an additional 20,871 shares in the last quarter. 67.65% of the stock is currently owned by institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.